EXEL News and Press, Exelixis Inc.

– Presentation to be webcast on www.exelixis.com – Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the William Blair 44 th Annual Growth Stock Conference on Tuesday, June 4 at 4:20 p.m. ET / 3:20 p.m. CT ...

2024-05-20 20:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-20 11:10:20 ET More on Exelixis Exelixis: With Patent Litigation Decision Due Soon, There Are Options Exelixis files patent suit against India’s Cipla over Cabometyx generics Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024 ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Cipla Ltd. and Cipla USA, Inc. (collectively Cipla). This settlement resolves two patent litigations brought by Exelixis in response to Cipla’s Abbreviated New Drug ...

2024-05-12 13:25:00 ET Many billionaire investors are going all in on artificial intelligence (AI). That's understandable. AI is quickly being integrated into businesses' day-to-day operations. The leaders in the field could deliver outsized returns. However, there are other exciting invest...

2024-05-11 15:23:49 ET More on Exelixis Exelixis: With Patent Litigation Decision Due Soon, There Are Options Exelixis, Inc. (EXEL) Q1 2024 Earnings Call Transcript Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024 Exelixis down 7% a...

2024-05-10 20:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-08 10:30:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips From its stellar performance in 2021 to deflating in 2022, the biotech sector continued its stagnation into 2023, highlighting some pharma stocks to avoid. Year-to-date, the S&P Biotechnolo...

- Presentations to be webcast on www.exelixis.com - Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in May: BofA Securities 2024 Health Care Conf...

2024-05-02 12:28:33 ET Summary EXEL continues to successfully implement Farallon's restructuring suggestions. A pivotal decision on cabo's current patent litigation is due by end of 1H'24. Multiple billions of potential revenue are at stake. I'm not holding shares through the ...